Christine Will

Christine Will

Auto-generated profile, based on publicly available information

Christine Will

AbbVie Inc 1 N. Waukegan Rd. North Chicago Illinois

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
The activated B cell (ABC) subset of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic B-cell receptor signaling and associated with poor outcomes when treated with standard therapy. In ABC-DLBCL, MALT1 is a core enzyme that is constitutively activated by stimulation of the B-cell receptor or gain-of-function mutations in upstream components of the signaling pathway, making it an attractive therapeutic target. We discovered a novel small-molecule inhibitor, ABBV-MALT1, that potently shuts down B-cell signaling selectively in ABC-DLBCL preclinical models leading to potent cell growth and xenograft inhibition. We also identified a rational combination partner for ABBV-MALT1 in the BCL2 inhibitor, venetoclax, which when combined significantly synergizes to elicit deep and durable responses in preclinical models. This work highlights the potential of ABBV-MALT1 monotherapy and combination with venetoclax as effective treatment options for patients with ABC-DLBCL.

2 July 2024
Verified
Other
Open access
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
Supplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma

2 July 2024
Verified
Other
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
Efficacy of ABBV-MALT1 across non-GCB PDX models

2 July 2024
Verified
Other
Open access
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
Excel Workbook ABBV-MALT1 Pharmacology

2 July 2024
Verified
Other
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
Efficacy of ABBV-MALT1 the OCI-LY10 CDX model

2 July 2024
Verified
Other
Open access
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
Supplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma